Fresenius SE & Co. KGaA



 


WELCOME TO FRESENIUS SE

Fresenius - the health care group

Fresenius is a global health care group with products and services for dialysis, the hospital and the medical care of patients at home.

The Fresenius Group consists of the following four business segments that are responsible for their own business operations worldwide: Fresenius Medical Care, Fresenius KabiFresenius Helios and Fresenius Vamed.


Latest news

25.02.2015
Sales and net income reach all-time highs – 6% dividend increase proposed – Positive Group outlook for 2015
Ulf Mark Schneider, CEO of Fresenius, said: „2014 was a challenging but successful year for Fresenius. We made significant progress on the integration of the Rhön hospitals, strengthened the Care Coordination initiatives at Fresenius Medical Care, and set new sales and earnings records for the Group. (...)” >>>
25.02.2015
Fresenius Medical Care reports fourth quarter and full year 2014 results
Rice Powell, chief executive officer of Fresenius Medical Care, stated: “During fiscal year 2014, we continuously improved our results and delivered on revenue and net income guidance. We have strengthened our core business and also expanded our portfolio with acquisitions in the field of care coordination. (...)" >>>
16.02.2015
Fresenius Kabi sells German oncology compounding business

Fresenius Kabi has sold its German subsidiary CFL GmbH to NewCo Pharma GmbH, a compounding company founded by pharmacist Michael Schill. Both companies specialize in IV oncology drug compounding.

>>>
29.01.2015
Change in Investor Relations Management

Birgit Grund, Senior Vice President of Investor Relations at Fresenius for the past 24 years, plans to leave the Company on March 31, 2015, to pursue a new opportunity. Markus Georgi will succeed Birgit Grund as Senior Vice President of Investor Relations, effective April 1, 2015. He has worked in Investor Relations for more than 15 years and will join Fresenius from Celesio AG, where he is currently Director Investor Relations.

>>>
19.01.2015
Fresenius refinances its credit agreement – Standard & Poor’s upgrades Fresenius’ credit rating to investment grade

Fresenius has launched a refinancing of the revolving facilities and the term loan A tranches (aggregate volume approx. €3 bn) under its 2013 senior credit agreement. The maturity will be extended by 2 years to June 28, 2020. Given the improved credit profile and favorable bank market conditions, Fresenius’ proposal also includes reduced credit margins.

>>>